Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme

NCT00209989 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma Multiforme

Interventions

DRUG: Zarnestra
PROCEDURE: standard Radiation therapy

Sponsor

Institut Claudius Regaud

Collaborators

[object Object]